Dostarlimab (Jemperli) — immunotherapy for endometrial cancer

What is dostarlimab (Jemperli) in simple words

Dostarlimab (Jemperli) is an immunotherapy drug. It does not work like chemotherapy.

Instead of directly attacking fast-dividing cells, it helps the immune system recognise cancer cells that have learned how to hide.

The drug blocks PD-1, a checkpoint receptor on immune cells. When this checkpoint is blocked, T-cells may stay active for longer and react more strongly against the tumour.

This is most relevant when the tumour has certain repair defects, especially dMMR or MSI-H. But even then, the decision is never made from one marker alone.

How dostarlimab works

PD-1 is part of the immune system’s braking system. It normally prevents excessive inflammation and protects healthy tissue.

Some tumours use this same pathway to calm down T-cells before they can attack. Dostarlimab binds to PD-1 and blocks signals from PD-L1 and PD-L2.

When the brake is lifted, immune cells may detect the tumour more clearly. In dMMR or MSI-H cancers, this can matter a great deal because these tumours often carry many abnormal signals that the immune system can recognise.

The key word is “may”. A biomarker can make response more likely, but it does not guarantee it. Stage, previous treatment, tumour burden and general condition still shape the plan.

What conditions dostarlimab is used for

Dostarlimab is mainly discussed in endometrial cancer and selected dMMR solid tumours.

• primary advanced or recurrent endometrial cancer — usually with carboplatin and paclitaxel first, then dostarlimab maintenance;
• dMMR or MSI-H recurrent or advanced endometrial cancer after platinum-based treatment;
• dMMR recurrent or advanced solid tumours after prior treatment when there are no satisfactory alternatives — in selected regulatory settings;
• clinical trial settings where PD-1 blockade is being studied in biomarker-defined disease.

This is not a “one drug for every cancer” situation. The same brand name may mean different uses depending on the country, the line of therapy and whether dMMR/MSI-H has been confirmed.

When dostarlimab may be especially relevant

The drug becomes most relevant when the biology of the tumour supports immune treatment.

• newly diagnosed advanced endometrial cancer where systemic therapy is needed;
• recurrent endometrial cancer where surgery or radiation alone will not control the disease;
• dMMR or MSI-H tumour status confirmed by a validated test;
• progression after platinum chemotherapy in the recurrent or advanced setting;
• a need to compare chemotherapy alone with chemotherapy plus immunotherapy;
• situations where maintenance immunotherapy after chemotherapy is being considered.

In endometrial cancer, this question often comes up at a turning point: the disease is no longer only a surgical problem, and the treatment plan has to look at the whole body.

For dMMR tumours, dostarlimab can be a very logical option. For pMMR disease, the discussion is different. It may still be relevant in the frontline endometrial setting, but the expected benefit and the risks need a careful review.

What needs to be checked before starting treatment

Before dostarlimab is chosen, the oncologist usually needs more than the name of the diagnosis.

• histology and grade of the tumour;
• stage and sites of disease;
• current CT, MRI or PET-CT results;
• MMR and MSI status;
• HER2 status in selected endometrial cancer subtypes;
• previous surgery, radiation and systemic treatment;
• full blood count and blood chemistry;
• liver, kidney and thyroid function;
• autoimmune disease history;
• current steroids or immunosuppressive medicines.

I also want to know how the patient is doing day to day. A scan can look technically “treatable”, while the person in front of you is too frail for a difficult combination. That changes the conversation.

How treatment is carried out

Jemperli is given as an intravenous infusion. In frontline endometrial cancer, it is commonly used together with carboplatin and paclitaxel for the chemotherapy phase, followed by dostarlimab alone as maintenance.

As monotherapy, the schedule is different. The exact dosing interval depends on the approved regimen, country and clinical situation.

During treatment, the team usually follows:

• blood counts and chemistry;
• thyroid tests — especially TSH and free T4;
• liver enzymes and bilirubin;
• kidney function;
• symptoms suggesting immune-related inflammation;
• CT, MRI or PET-CT response assessment.

When dostarlimab is given with chemotherapy, side effects can come from either part of the treatment. Hair loss or low blood counts usually point more toward chemotherapy. Colitis, pneumonitis or thyroiditis point more toward immune activation.

Possible side effects

Dostarlimab can cause ordinary treatment side effects and immune-related side effects. The second group is the one that needs special attention.

• fatigue;
• nausea, reduced appetite or constipation;
• rash, itching or dry skin;
• diarrhoea or colitis;
• thyroid changes;
• inflammation of the lungs — pneumonitis;
• liver inflammation with raised liver enzymes;
• kidney inflammation;
• adrenal or pituitary hormone problems;
• rare neurological, cardiac or severe skin reactions.

Most immune side effects are easier to manage when reported early. Waiting until the next scheduled visit is usually the wrong instinct if the symptom is new, persistent or getting worse.

When to contact a doctor urgently

Contact the treating team promptly if any of these appear during treatment:

• new or worsening shortness of breath;
• persistent cough;
• diarrhoea several times a day or blood in the stool;
• yellow skin or dark urine;
• fever above 38°C;
• severe weakness or dizziness;
• confusion, severe headache or vision changes;
• new chest pain or palpitations;
• rapidly spreading rash;
• any sudden deterioration that feels unusual.

With immunotherapy, the safest rule is simple: call early. Not every symptom is dangerous, but the dangerous ones should not be found late.

Why dostarlimab is not right for everyone

A PD-1 inhibitor can be a strong option, but it is not automatically the right option.

• the tumour may not have the biology that makes immunotherapy useful;
• other treatment may be more appropriate first;
• active autoimmune disease can increase risk;
• a solid organ transplant creates a rejection risk;
• severe lung, liver or endocrine disease may complicate treatment;
• the patient may not be fit enough for chemotherapy combination.

This is where a real oncology decision differs from a drug description. The question is not “Can the drug be used?” The question is whether it is the best risk-benefit choice for this patient now.

Can dostarlimab be combined with other treatments

Yes. In endometrial cancer, the important approved combination is dostarlimab with carboplatin and paclitaxel, followed by dostarlimab alone.

That sequence matters. Chemotherapy can reduce tumour burden quickly. Immunotherapy may then help keep immune pressure on the disease during maintenance.

Other combinations are being studied, including combinations with PARP inhibitors or other targeted approaches. These should not be treated as interchangeable with approved regimens. The evidence has to match the diagnosis and biomarker profile.

What “no quick response” to treatment means

Immunotherapy is rarely judged after one infusion. It needs time.

Sometimes scans show stable disease first. Sometimes symptoms improve before the imaging looks impressive. Occasionally, inflammation around the tumour can make early imaging difficult to interpret.

I usually look at the scan together with symptoms, blood tests and the pace of the disease before treatment. One picture can raise concern. It should not automatically replace the whole clinical story.

Oncology consultation for dostarlimab (Jemperli) in Israel

At Tel Aviv Medical Clinic in Israel, patients can receive an oncology consultation on the possible role of dostarlimab (Jemperli) in endometrial cancer and selected dMMR or MSI-H tumours.

A consultation may be useful if you need to:

• understand whether Jemperli fits your diagnosis;
• review MMR, MSI and other biomarker results;
• compare chemotherapy alone with chemo-immunotherapy;
• get a second opinion after recurrence;
• review options after platinum-based treatment;
• plan questions for your treating oncologist.

We do not replace your treating physician. We help clarify the logic of the treatment plan so the next decision is not made blindly.

Frequently Asked Questions — Dr. Stefanskoy

1. Is dostarlimab only for endometrial cancer?

Most practical discussions are about endometrial cancer. That is where the drug has become especially important. In some settings it can also be used for dMMR recurrent or advanced solid tumours after prior treatment, when there are no satisfactory options. I would not present it as a general cancer drug.

2. What does dMMR or MSI-H mean?

It means the tumour has a defect in DNA repair. Because of that, cancer cells may accumulate many mutations. The immune system can sometimes recognise these abnormal signals more easily, which is why PD-1 treatment may work particularly well in this group.

3. Can Jemperli replace chemotherapy?

Sometimes it is used alone, especially after previous platinum treatment in dMMR disease. But in newly diagnosed advanced or recurrent endometrial cancer, it is often used with carboplatin and paclitaxel first. So no, I would not say it simply replaces chemotherapy. The setting matters.

4. How soon can we know whether it works?

Usually after several cycles and a planned scan. I also listen to symptoms: pain, bleeding, appetite, energy level, shortness of breath. A scan is important, but it is not the only piece of information.

5. Is dostarlimab safer than chemotherapy?

It is different, not automatically safer. Chemotherapy has one pattern of toxicity. Immunotherapy can inflame healthy organs. Thyroid problems, colitis, pneumonitis and hepatitis are not “minor” if they are missed.

6. What if the patient has an autoimmune disease?

Then I slow down the decision. Some patients can still receive immunotherapy, but active autoimmune disease increases the risk of flare. I would want to know the exact diagnosis, current activity and medications before giving an opinion.

7. What happens after dostarlimab stops working?

That depends on what was used before. Options may include chemotherapy, targeted therapy, hormonal therapy in selected endometrial cancers, a clinical trial, or local treatment for limited progression. There is no single next step.

Important information

The information on this page is for general medical reference only and does not constitute a treatment recommendation. Dostarlimab (Jemperli) may only be prescribed by an oncologist after assessment of diagnosis, disease stage, biomarker results, previous treatment and overall patient condition.

Do not start, stop or change treatment without consulting your treating physician.

To arrange an oncology consultation regarding immunotherapy and the potential use of dostarlimab in Israel:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108